How should children be treated with peanut allergy?
Recently, there is increasing evidence that children with peanut allergy should gradually increase peanut intake to reduce the severity of the disease. However, according to recent findings, such a gradual increase may make the situation even worse.
A recent study by McMaster University found that a gradual increase in peanut intake in children with peanut allergy could increase the severity of the disease. The results of the study were published in the journal The Lancet in English.
Oral peanut immunotherapy has increased the triple rate of anaphylaxis
Past studies of food problems have shown that oral immunotherapy, which gradually increases the dose of allergens over time, can be quite effective. However, a recent survey by the University of Macmaster raises suspicions about this approach. It has been shown that attempts to desensitize children in the real world promote allergic reactions, including severe and potentially fatal anaphylaxis, compared to completely avoiding contact with peanuts. The researchers found that oral peanut immunotherapy increased the triple rate of anaphylaxis from about 7.1 percent to a healthy 22.2 percent. Allergic reactions that led to vomiting, abdominal pain, itching in the mouth, rash and asthma, increased significantly.
The safety of oral immunotherapy should be improved
Various studies of different quality for oral immunotherapy have been published, but the efficacy and reliability of treatment remain unclear, according to the authors in the current study. The new study includes all previous randomized clinical trials in which oral peanut therapy is compared with unimunotherapy for best possible evidence-taking evidence. It has been shown that current oral immunotherapeutic approaches to peanuts can achieve the immune target for desensitization, but this does not result in achieving the desired goal of avoiding an allergic response and anaphylaxis.
On the contrary, the opposite occurs, with more allergic and adverse reactions in oral immunotherapy than avoiding contact with peanuts or taking a placebo, the authors explain. Findings do not condemn ongoing research in the field of oral immunotherapy, but the method should be carefully examined, safety should be improved, and success factors should meet the desires of affected individuals, researchers say.
Many allergies are overcome during early life
In Europe and North America, more than six million people are affected by food allergies, including eight percent of children and two to three percent of adults. While allergies to milk and eggs are often overcome at the age of five to ten years, peanut allergy can be a lifelong problem for patients. Oral immunotherapy studies measure success in the treatment of whether the patient tolerates the controlled allergenic challenge. However, this can not predict the future risk in the real world, researchers say.
Oral or epicutaneous immunotherapy?
The results of the oral (through the mouth) and epicutaneous (contact skin) immunotherapy should be compared. Although epicutaneous immunotherapy is less effective, it has a better security profile than oral immunotherapy, explains the researchers. It should not be forgotten that the early introduction of peanut products in baby food can prevent most cases of peanut allergy. However, better strategies need to be developed to reduce the number of patients with an existing peanut allergy. (How)